Posts

AlgiPharma signs new license agreement with NTNU

AlgiPharma signed a new license agreement securing exclusive the global rights for the OligoG patent portfolio from the Norwegian University of Science and Technology (NTNU) for all disease areas and medical applications, except non-inhalation treatment in oncology.

Yngvar P. Berg, CEO; yngvar.berg@algipharma.com

March 9, 2016